(-0.06%) 5 143.75 points
(-0.02%) 38 553 points
(0.00%) 17 905 points
(-0.23%) $82.44
(1.72%) $2.07
(-1.05%) $2 333.00
(-2.11%) $27.08
(-0.48%) $956.90
(0.16%) $0.934
(0.34%) $11.02
(0.21%) $0.798
(-0.21%) $93.11
2 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 5.42%
@ $45.58
Išleistas: 14 vas. 2024 @ 22:47
Grąža: -3.41%
Ankstesnis signalas: vas. 14 - 16:30
Ankstesnis signalas:
Grąža: 2.09 %
Live Chart Being Loaded With Signals
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally...
Stats | |
---|---|
Šios dienos apimtis | 552 586 |
Vidutinė apimtis | 696 204 |
Rinkos kapitalizacija | 3.62B |
EPS | $0 ( 2024-02-15 ) |
Kita pelno data | ( $-1.730 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.34 |
ATR14 | $0.0330 (0.07%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | Crombez Eric | Sell | 142 | Common Stock |
2024-04-16 | Huizenga Theodore Alan | Sell | 14 | Common Stock |
2024-03-11 | Kassberg Thomas Richard | Sell | 11 509 | Common Stock |
2024-03-07 | Fust Matthew K | Sell | 2 550 | Common Stock |
2024-03-07 | Fust Matthew K | Sell | 2 145 | Common Stock |
INSIDER POWER |
---|
45.65 |
Last 99 transactions |
Buy: 915 632 | Sell: 371 334 |
Tūris Koreliacija
Ultragenyx Pharmaceutical Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
GAINL | 0.862 |
ITMR | 0.852 |
DVCR | 0.847 |
AVEO | 0.845 |
ISNS | 0.842 |
VLYPP | 0.831 |
CHMA | 0.825 |
OPNT | 0.825 |
SUMR | 0.813 |
EDUT | 0.813 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
SHSP | -0.9 |
BOCH | -0.891 |
XFOR | -0.833 |
GRCL | -0.833 |
ENPH | -0.827 |
RDHL | -0.82 |
THTX | -0.819 |
PTPI | -0.805 |
QTEK | -0.801 |
BLU | -0.801 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Ultragenyx Pharmaceutical Koreliacija - Valiuta/Žaliavos
Ultragenyx Pharmaceutical Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $434.25M |
Bruto pelnas: | $389.04M (89.59 %) |
EPS: | $-8.25 |
FY | 2023 |
Pajamos: | $434.25M |
Bruto pelnas: | $389.04M (89.59 %) |
EPS: | $-8.25 |
FY | 2022 |
Pajamos: | $363.33M |
Bruto pelnas: | $335.01M (92.21 %) |
EPS: | $-10.12 |
FY | 2021 |
Pajamos: | $351.41M |
Bruto pelnas: | $335.40M (95.44 %) |
EPS: | $-6.70 |
Financial Reports:
No articles found.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.